Overview

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Status:
Completed
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess the effect of empagliflozin on cardiac physiology and metabolism aiming to provide a scientific explanation of the underlying mechanism by which empagliflozin improves HF related outcomes in patients with chronic heart failure
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Treatments:
Empagliflozin